<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351607</url>
  </required_header>
  <id_info>
    <org_study_id>2020001</org_study_id>
    <nct_id>NCT04351607</nct_id>
  </id_info>
  <brief_title>Preoperative Supplementation of Sucrosomal Iron as Hematopoietic Support.</brief_title>
  <acronym>Preop Iron</acronym>
  <official_title>Einfluss Eines Oralen Eisenpräparats Mit Hoher Bioverfügbarkeit (OLEOvital® EISEN FORTE) Auf Die präoperative Hämoglobinkonzentration Bei anämischen Patienten</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mein Hanusch-Krankenhaus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mein Hanusch-Krankenhaus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prove, if preoperative elective anemic patients improve their hemoglobin levels within 3-6&#xD;
      weeks preoperativly after daily oral dietary supplementation of 60mg sucrosomal iron.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with preoperative anemia have a poorer perioperative outcome in morbidity and&#xD;
      mortality as part of surgery. Oral iron preparations have so far had poor bioavailability&#xD;
      (approx. 30%) and mostly gastrointestinal side effects that often lead to discontinuation of&#xD;
      treatment. Intravenous iron preparations also have an increased risk of allergic disease,&#xD;
      which has already led to deaths in Austria. Oleovital® Eisen Forte shows improved&#xD;
      bioavailability and hardly any gastrointestinal side effects. It should be improved in anemic&#xD;
      patients by oleovital iron forte the hemoglobin content of the blood before surgery.&#xD;
      Preoperative anemia is a relatively common problem that has not been preoperatively treated&#xD;
      so far and therefore studies such as the one present here are very relevant.&#xD;
&#xD;
      The dietary supplement (Oleovital® Eisen Forte) has been on the market in Austria for iron&#xD;
      substitution since autumn 2016. Oleovital® Eisen Forte seems suitable to produce a&#xD;
      physiological hemoglobin content. The improved galenics is without previously known&#xD;
      gastrointestinal side effects and should be investigated in an oral dose of 2 x 30mg (=60mg)&#xD;
      p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand.&#xD;
&#xD;
      The main objective of the study following a confirmant approach is to verify whether a&#xD;
      sufficiently high number of anemic patients benefit from the oral intake of a high&#xD;
      bioavailability iron preparation (Oleovital® Eisen Forte) in the last three to six weeks&#xD;
      before an elective intervention (profit = response = increase in hemoglobin concentration by&#xD;
      at least 1g/dl).&#xD;
&#xD;
      This controlled, randomized, open, prospective, monocentric study (two-armed parallel group&#xD;
      design) should be classified as a food study (application of the commercial dietary&#xD;
      supplement Oleovital® Eisen Forte) in an interventional setting - study-specific measures:&#xD;
      additional blood tests and intake of Oleovital® Eisen Forte, in certain cases additional for&#xD;
      a study-specific blood test are re-quired.&#xD;
&#xD;
      There are two study arms or groups:&#xD;
&#xD;
        -  Group V = Verumgroup with iron supplementation by Oleovital® Eisen Forte&#xD;
&#xD;
        -  Group K = Control group without iron supplementation - This group receives the usual&#xD;
           treatment in the hospital.&#xD;
&#xD;
      Furthermore, stratification is carried out according to the sub-collectives&#xD;
&#xD;
        -  &quot;Patients without menstrual bleeding&quot; (subcollective A) and&#xD;
&#xD;
        -  &quot;Patients with menstrual bleeding&quot; (subcollective B)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemoglobin</measure>
    <time_frame>3 - 6 weeks</time_frame>
    <description>1 g/dl increase</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anemia, Iron-Deficiency</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dose of 2 x 30mg (=60mg) Oleovital® Eisen Forte p.o. per day over a limited intake of 3-6 weeks due to increased physiological iron demand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with menstral bleeding - subcollective A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>verum or control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient without menstral bleeding - subcollective B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>verum or control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oleovital® Eisen Forte</intervention_name>
    <description>60 mg daily oral Supplementation for 3 to 6 weeks</description>
    <arm_group_label>Patient with menstral bleeding - subcollective A</arm_group_label>
    <arm_group_label>Patient without menstral bleeding - subcollective B</arm_group_label>
    <arm_group_label>Verum</arm_group_label>
    <other_name>Verum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent according to previous written and oral clarification&#xD;
&#xD;
          -  Elective intervention in 3-6 weeks&#xD;
&#xD;
          -  Hemoglobin (Hb) -12.0g/dl&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Non-cardiac surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-business capability or legal representation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding period&#xD;
&#xD;
          -  Chronic diarrhoea (&gt; 4 weeks)&#xD;
&#xD;
          -  Known massive absorption restriction (e.g. short bowel syndrome)&#xD;
&#xD;
          -  Known or suspected fructose intolerance&#xD;
&#xD;
          -  Iron accumulation disorders: hemochromatosis, hemosiderosis&#xD;
&#xD;
          -  Vegan diet&#xD;
&#xD;
          -  Use of a preparation to specifically increase the body's own erythrocyte or hemoglobin&#xD;
             concentration or production (e.g. EPO preparations, erythrocyte concentrates) in the&#xD;
             last 4 weeks&#xD;
&#xD;
          -  Permanent or preoperativeblood loss (e.g. seepage bleeding)&#xD;
&#xD;
          -  Intended intake/application of another iron-supplementing preparation before surgery&#xD;
&#xD;
          -  Intended use of preparations to specifically increase the body's own erythrocyte or&#xD;
             hemoglobin concentration or production (e.g. EPO preparations, erythrocyte&#xD;
             concentrates) prior to surgery&#xD;
&#xD;
          -  Simultaneous participation in another clinical trial with insurance cover&#xD;
&#xD;
          -  Foreseeable compliance issues&#xD;
&#xD;
          -  Existing refractory disorder of the bone marrow: myelodysplasia&#xD;
&#xD;
          -  In the case of conspicuous base laboratory towards undiagnosed hemochromatosis:&#xD;
             increased plasma iron, increased serum ferritin and increased transferrin saturation&#xD;
             without increased signs of inflammation (CRP), the patient is assigned to the&#xD;
             hematological department of the Hanusch Hospital for further diagnosis.&#xD;
&#xD;
          -  Acutely therapeutic anemia Hb x 8 g/dl (indication for a mandatory correction of the&#xD;
             Hb to a clinically safe or non-therapeutic value - no randomization into the control&#xD;
             group makes sense)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>with or without menstral bleeding</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander Loeckinger, M.D.</last_name>
    <phone>+43191021</phone>
    <phone_ext>57158</phone_ext>
    <email>alexander.loeckinger@oegk.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Engelbert Deusch, M.D.</last_name>
    <phone>+43191021</phone>
    <phone_ext>57162</phone_ext>
    <email>engelbert.deusch@oegk.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anestesiology and Critical Care Medicine</name>
      <address>
        <city>Vienna</city>
        <state>Penzing</state>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Loeckinger, M.D.</last_name>
      <phone>+43191021</phone>
      <phone_ext>57158</phone_ext>
      <email>alexander.loeckinger@oegk.at</email>
    </contact>
    <contact_backup>
      <last_name>Engelbert Deusch, M.D.</last_name>
      <phone>+43191021</phone>
      <phone_ext>57162</phone_ext>
      <email>engelbert.deusch@oegk.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mein Hanusch-Krankenhaus</investigator_affiliation>
    <investigator_full_name>Alexander Löckinger MD., Msc.</investigator_full_name>
    <investigator_title>M.D. MSc.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

